Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK2 V617F allele burden in polycythemia vera: burden of proof
Alison R. Moliterno, Hannah Kaizer, Brandi Reeves
Blood (2023) Vol. 141, Iss. 16, pp. 1934-1942
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2129-2132
Open Access | Times Cited: 33
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
Paola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1550-1559
Closed Access | Times Cited: 11
Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment
Albert Qin
Clinical Therapeutics (2024) Vol. 46, Iss. 5, pp. 439-440
Closed Access | Times Cited: 8
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
Aaron T. Gerds, Ruben A. Mesa, John M. Burke, et al.
Blood (2023) Vol. 143, Iss. 16, pp. 1646-1655
Open Access | Times Cited: 19
JAK2V617Fmutation is highly prevalent in patients with ischemic stroke: a case-control study
Marie Hvelplund Kristiansen, Lasse Kjær, Vibe Skov, et al.
Blood Advances (2023) Vol. 7, Iss. 19, pp. 5825-5834
Open Access | Times Cited: 18
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
S. Suo, Rong Feng Fu, Albert Qin, et al.
Journal of Hematology (2024) Vol. 13, Iss. 1-2, pp. 12-22
Open Access | Times Cited: 7
Moving toward disease modification in polycythemia vera
Jan Philipp Bewersdorf, Joan How, Lucia Masarová, et al.
Blood (2023) Vol. 142, Iss. 22, pp. 1859-1870
Closed Access | Times Cited: 15
Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera
Albert Qin, Daoxiang Wu, Yaning Li, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 6, pp. 1493-1502
Closed Access | Times Cited: 4
Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
Chih‐Cheng Chen, Justin L. Chen, Alex Jia-Hong Lin, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 1947-1965
Open Access | Times Cited: 4
Clearance of Driver Mutations after Transplantation for Myelofibrosis
Nico Gagelmann, Marie Quarder, Anita Badbaran, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 150-160
Closed Access
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
Abdulraheem Yacoub, Ghaith Abu‐Zeinah, Albert Qin, et al.
Annals of Hematology (2025)
Open Access
Multiple Aneurysms and Thrombotic Events as Initial Manifestations of Primary Myelofibrosis: A Case Report
Konstantinos Manganas, Thrasyvoulos Bemplidakis, K. Papachristou, et al.
Cureus (2025)
Open Access
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, et al.
International Journal of Cancer (2025)
Open Access
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
Paola Barone, Adele Bottaro, Rossana Leanza, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 227-227
Open Access
Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms
Laura Calabresi, Chiara Carretta, Simone Romagnoli, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1520-1531
Open Access | Times Cited: 11
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b
Kazuya Shimoda, Albert Qin, Norio Komatsu, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 2, pp. 151-156
Open Access | Times Cited: 3
Genetic mutations in pyoderma gangrenosum, hidradenitis suppurativa, and associated autoinflammatory syndromes: Insights into pathogenic mechanisms and shared pathways
Takashi Satoh
The Journal of Dermatology (2023) Vol. 51, Iss. 2, pp. 160-171
Open Access | Times Cited: 7
Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2V617F Mutation
Yupeng Liu, Cong Han, Jie Li, et al.
Global Medical Genetics (2024) Vol. 11, Iss. 02, pp. 132-141
Open Access | Times Cited: 2
Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia
Keita Kirito, Albert Qin, Shanshan Suo, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Suppression of FOXC1 induces pyroptosis of the coronary artery through activation of JAK2
Jiayun Qiu, Yahong Fu, Ting Tian, et al.
Atherosclerosis (2024) Vol. 396, pp. 118543-118543
Open Access | Times Cited: 2
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Ghaith Abu‐Zeinah, Albert Qin, Harinder Gill, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3573-3583
Open Access | Times Cited: 2
Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review
Qiongle Peng, Jinmei Zhu, Yanhu Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 19, pp. e38831-e38831
Open Access | Times Cited: 2
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b
Shanshan Suo, Rongfeng Fu, Albert Qin, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
Hans Carl Hasselbalch, Peter Junker, Vibe Skov, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4323-4323
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top